These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12534150)

  • 21. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
    Han JY; Kim JY; Lee SH; Yoo NJ; Choi BG
    Lung Cancer; 2011 Nov; 74(2):293-9. PubMed ID: 21440951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
    Ku GY; Haaland BA; de Lima Lopes G
    Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
    Baselga J
    J Clin Oncol; 2004 Mar; 22(5):759-61. PubMed ID: 14990627
    [No Abstract]   [Full Text] [Related]  

  • 33. Erlotinib in non-small cell lung cancer treatment: current status and future development.
    Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F
    Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.
    Vaidya AP; Parnes AD; Seiden MV
    Curr Treat Options Oncol; 2005 Mar; 6(2):103-14. PubMed ID: 15717992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
    Manegold C
    Adv Exp Med Biol; 2003; 532():247-52. PubMed ID: 12908563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
    Raben D; Helfrich BA; Chan D; Johnson G; Bunn PA
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):37-46. PubMed ID: 11894012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.